U.S. Contraceptive Market Size, Share, Growth Analysis, By Product(Pills, Intrauterine Devices (IUD) (Hormonal IUD), By Age-group(15-44 years, above 44 years), By End-User(Households, clinics) - Industry Forecast 2024-2031

US Contraceptive Market size was valued at USD 7.88 billion in 2019 and is poised to grow from USD 8.3 billion in 2023 to USD 12.15 billion by 2031, growing at a CAGR of 5.16% in the forecast period (2024-2031).

Attributed to the existence of multiple enterprises, the market is very competitive. Most businesses are pursuing strategic initiatives, such as R&D spending, in order to produce innovative goods and acquire a competitive advantage over rivals. High expenditures by well-known corporations in the commercialization of effective and long-term reversible contraception have raised public awareness of these products. 'Bayer AG', 'Pfizer Inc.', 'Merck & Co., Inc.', 'Allergan plc', 'Teva Pharmaceutical Industries Ltd.', 'Mylan N.V.', 'Church & Dwight Co., Inc.', 'Reckitt Benckiser Group plc', 'CooperSurgical, Inc.', 'Medicines360', 'Agile Therapeutics, Inc.', 'Afaxys, Inc.', 'HRA Pharma', 'TherapeuticsMD, Inc.', 'Apothecus Pharmaceutical Corporation', 'Mayer Laboratories, Inc.', 'The Female Health Company', 'Lumara Health Inc.', 'Veru Inc.', 'The Population Council, Inc.', 'On October 2022, to consider the application submitted by HRA Pharma, a Paris-based pharmaceutical company owned by the Perrigo Company, to make its progesterone-only mini-pill available in the U.S. without a prescription.', 'In July 2022, Evofem Biosciences, Inc. announced the creation of a new educational birth control chart that provides high-level information about the various options available to women in the United States.'

The introduction of more effective male contraception products is expected to boost contraceptive sales. Female contraceptives are currently the market leaders, but male contraceptives will see increased demand due to the increased use of male condoms.

Current oral contraceptive products also include novel progestins, which have changed the scope of benefits and side effects. Approximately half of all pregnancies in the United States are unintended, and more than one in every five pregnancies in the United States ends in abortion. A study of over 10,000 women who sought abortions discovered that 46% did not use a contraceptive method during the month they conceived. Extended-cycle COCs, drospirenone-containing products, chewable contraceptive pills, and emergency contraceptive options are among the recent contraceptive advances. Sterilization is the most popular method of contraception in the United States. Many women who choose sterilization before the age of 30 later express regret and report doing so because they were unaware of equally effective reversible alternatives. In the United States, combination oral contraceptives (COCs) are the most commonly used reversible form of birth control.

During the projection period, development, approval, and commercialization of novel, more effective, and long-acting reversible contraceptive techniques are likely to boost the market growth. Agile Therapeutics, for example, created Twirla, a hormonal patch that will be available in the United States in the fourth quarter of 2020. The availability of generic and low-cost medications and technologies has increased the need for contraception among teens. Furthermore, nonhormonal contraceptives are becoming increasingly popular in the United States since they reduce the danger of undesirable consequences linked with hormonal imbalance in the body. In 29 states, insurers must provide comprehensive coverage for FDA-approved contraceptive methods for women. Over-the-counter contraceptives are covered in 12 states; however, insurers may require a prescription from the beneficiary. In 20 states and the District of Columbia, insurers are required to cover a large number of contraceptives at once.